RoboCT develops and commercializes the UGO exoskeleton robot for rehabilitation and elderly care, combining intention-detection and multi-sensor information fusion technologies. The company was the first in China to obtain NMPA registration for lower-limb exoskeletons for central neuropathy and reports UGO devices in use in more than 200 hospitals. RoboCT operates a digital rehabilitation cloud platform and promotes a Robot-as-a-Service (RaaS) model to reduce therapist workload and improve training efficiency. The company says it is the only exoskeleton firm in the industry with mass production capacity and has produced more than 100,000 UGO exoskeleton robots to date. RoboCT has applied for over 100 intellectual property rights and received more than 20 awards. It plans to increase investment in product, talent, technology and supply chain, enrich its product matrix, expand its global footprint, and build an open consumer-facing operation platform.

Total raised

$16M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2022